Company: PSTV
Filing Date: 2025-04-01
Form Type: CORRESP
Source: 0001193125-25-070569
Chunk: 1

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: CORRESP
Chunk 1
---
 ( seepp. 13-16of the Amended Preliminary Proxy Statement). 2. We note your disclosure on page 16 that if stockholders approve the Issuance Proposal, assuming the full exercise of the Warrants at the floor price of $0.132, and assuming the Series B Warrants are exercised on an alternative cashless exercise basis, an aggregate of approximately 1,542,317,700 additional shares of common stock will be issued and the ownership interest of your existing stockholders would be correspondingly reduced. In each instance in your proxy statement where you describe Proposal 2, which is asking stockholders to approve the issuance of the common stock underlying such warrants, please clarify the total number of Series A and Series B warrants that were issued and the total number of common stock that may be issuable upon the exercise of those warrants, using the assumptions you disclose on page 16. In response to the Staff’s comment, the Company revised the disclosure in the Amended Preliminary Proxy Statement ( seethe Notice, pp. 2, 13, 15, and 16 of the Amended Preliminary Proxy Statement, and the preliminary proxy card). 3. We note your disclosure on page 13 that your Series A Warrants and Series B Warrants “are subject to a ‘reset’ provision” that may increase the number of shares of Common Stock underlying each Warrant. Please revise your disclosure to prominently disclose the material terms and conditions of the reset provision and explain the potential additional dilution upon the “reset.” In response to the Staff’s comment, the Company revised the disclosure in the Amended Preliminary Proxy Statement ( seepp. 13, 15, and 16 of the Amended Preliminary Proxy Statement). * * * Thank you for your attention to this letter. If you have any questions with respect to the foregoing, please contact the undersigned at (410) 659-2778.The Company would appreciate the Staff’s expeditious review of the Amended Preliminary Proxy Statement.

| Sincerely,            |
| /s/ William I. Intner |

| cc: | Marc H. Hedrick, M.D., President and Chief Executive Officer |

Andrew Sims, Chief Financial Officer Andrew Strong, Hogan Lovells US LLP